rs99780 — FADS2

FADS2 rs99780 — The Omega Conversion Bottleneck

The FADS2 gene encodes delta-6 desaturase¹¹ delta-6 desaturase
The enzyme responsible for the first rate-limiting step in converting dietary short-chain polyunsaturated fats into their biologically active long-chain forms — adding a double bond at the 6-position of the fatty acid chain, the enzyme that performs the first critical step in converting the essential fats you eat — linoleic acid (omega-6) from vegetable oils and alpha-linolenic acid (omega-3) from flaxseed and walnuts — into longer, more biologically active forms such as arachidonic acid (ARA), eicosapentaenoic acid (EPA), and ultimately docosahexaenoic acid (DHA). The rs99780 variant is an intronic single nucleotide polymorphism within the FADS1-FADS2 gene cluster²² FADS1-FADS2 gene cluster
A highly conserved genomic region on chromosome 11q12.2 containing FADS1, FADS2, and FADS3 in tandem — the most replicated GWAS locus for circulating fatty acid levels in humans on chromosome 11, a region consistently identified as the dominant genetic determinant of circulating polyunsaturated fatty acid (PUFA) composition across populations.

The Mechanism

rs99780 does not alter the FADS2 protein sequence — it is located within an intron. However, as part of the haplotype structure of the FADS cluster, it tags a regulatory state that influences FADS2 expression and delta-6 desaturase activity³³ FADS2 expression and delta-6 desaturase activity
Intronic and regulatory variants in the FADS cluster are thought to influence transcription factor binding and local chromatin state, modulating the amount of FADS2 enzyme produced rather than its structure or kinetics. The T allele at rs99780 co-segregates with minor alleles at neighboring FADS variants (rs174553, rs174575, rs174583) to form a haplotype associated with reduced FADS2 activity. The consequence of reduced delta-6 desaturase activity is a systemic shift in PUFA metabolism:

• Omega-6 pathway: Less linoleic acid (LA) is converted to gamma-linolenic acid (GLA) and then to arachidonic acid (ARA), the major omega-6 long-chain PUFA
• Omega-3 pathway: Less alpha-linolenic acid (ALA) is converted to stearidonic acid (SDA) and then toward EPA — reducing endogenous EPA synthesis from plant-based omega-3 sources

The net result is accumulation of precursor fatty acids (LA, ALA) and depletion of long-chain products (ARA, EPA), a pattern directly measurable in blood and tissue phospholipids.

The Evidence

The foundational evidence for rs99780 specifically comes from a study by Xie and Innis⁴⁴ Xie and Innis
Xie L, Innis SM. Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J Nutr, 2008 in 69 pregnant Canadian women. The study directly genotyped rs99780 among four FADS cluster variants. Women homozygous for the minor alleles at rs99780 showed lower ARA but higher LA in plasma phospholipids and erythrocyte ethanolamine phospholipids at 16 and 36 weeks of gestation, alongside decreased product-to-precursor ratios for both omega-6 (ARA/LA) and omega-3 (EPA/ALA) pathways. In breast milk, TT homozygotes showed significantly lower ARA and EPA — indicating that the conversion impairment persists through lactation and affects the fatty acid composition of milk provided to infants.

The broader context for this locus is established by Tanaka and colleagues⁵⁵ Tanaka and colleagues
Tanaka T et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 in 1,075 InCHIANTI participants — the landmark GWAS demonstrating that the FADS chromosome 11 locus explains a remarkable 18.6% of additive variance in arachidonic acid levels, with genome-wide significant associations extending across multiple PUFA species. The same cluster harboring rs99780 was the top hit for EPA levels and several related fatty acids, confirming this region's central role in PUFA metabolism.

A key clinical dimension emerged from childhood cohort data: Talaei and colleagues⁶⁶ Talaei and colleagues
Talaei M et al. Intake of n-3 polyunsaturated fatty acids in childhood, FADS genotype and incident asthma. Eur Respir J, 2021 examined 4,543 children from the AVON Longitudinal Study and found that among minor allele carriers at a linked FADS2 variant (rs1535, in LD with rs99780), higher EPA+DHA intake in childhood was associated with a 51% reduction in asthma risk (OR 0.49, 95%CI 0.31–0.79; p-interaction = 0.006). Among major allele homozygotes — who can efficiently synthesize their own long-chain omega-3 from plant ALA — no protective effect was found (OR 1.43), suggesting that supplemental EPA/DHA specifically benefits those who cannot make it endogenously.

A review of the evidence by O'Neill and Minihane⁷⁷ O'Neill and Minihane
O'Neill CM, Minihane AM. The impact of fatty acid desaturase genotype on fatty acid status and cardiovascular health in adults. Proc Nutr Soc, 2017 confirmed the consistent pattern: FADS minor allele carriers have higher plasma and tissue concentrations of LA and ALA (precursors), lower ARA, lower EPA, and somewhat lower DHA. Critically, dietary total fat and fatty acid composition modifies these relationships — indicating that diet can amplify or attenuate the genetic effect.

Practical Actions

The core implication is straightforward: people carrying the T allele at rs99780 have a genetically limited capacity to convert plant-based omega-3 and omega-6 fatty acids into their long-chain active forms. This makes preformed EPA and DHA from marine sources or algae supplements more important than for people with full FADS2 activity. Plant-based omega-3 sources (flaxseed, chia, walnuts) supply only ALA, which requires the impaired FADS2 → delta-6 desaturase step to reach EPA. Relying on these sources as the primary omega-3 strategy is insufficient for T allele carriers.

The gene-nutrient interaction data also suggest that EPA/DHA supplementation may provide health benefits in T allele carriers that do not apply equally to CC homozygotes — including potential protection against atopic conditions and inflammatory outcomes.

Interactions

rs99780 is part of the FADS1-FADS2 haplotype block that includes rs174537 and rs174547 (both already in the GeneOps platform). These variants are in partial linkage disequilibrium (LD) and may produce additive effects when co-inherited. rs174537 (FADS1, in the triglycerides-fatty-acids category) specifically affects delta-5 desaturase activity — the downstream step converting DGLA to ARA and ETA to EPA. Carrying impaired alleles at both FADS2 (rs99780) and FADS1 (rs174537/rs174547) compounds the disruption across the full PUFA elongation cascade, potentially creating a more severe functional omega-3/omega-6 deficiency than either variant alone.

rs174575 (FADS2) and rs1535 (FADS2) are additional SNPs in the cluster not yet in the platform that may provide further resolution on FADS2 activity.